Denali Therapeutics Inc. (NASDAQ:DNLI) Stock Has Consensus Price Target of $35.85

Denali Therapeutics Inc. (NASDAQ:DNLI) has been assigned an average rating of “Moderate Buy” from the sixteen ratings firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have issued a buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $35.85.

DNLI has been the subject of a number of analyst reports. Morgan Stanley raised their price target on Denali Therapeutics from $35.00 to $36.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Sanford C. Bernstein reissued a “hold” rating on shares of Denali Therapeutics in a report on Monday, June 22nd. UBS Group raised their price objective on shares of Denali Therapeutics from $25.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Wedbush reaffirmed an “outperform” rating and set a $26.00 price objective on shares of Denali Therapeutics in a research note on Monday, July 13th. Finally, JPMorgan Chase & Co. began coverage on shares of Denali Therapeutics in a report on Monday, July 13th. They set an “overweight” rating and a $29.00 target price on the stock.

Insider Buying and Selling

In other news, insider Alexander O. Schuth sold 2,857 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total transaction of $71,624.99. Following the completion of the transaction, the insider directly owned 281,763 shares in the company, valued at $7,063,798.41. The trade was a 1.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 9.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Denali Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Engineers Gate Manager LP boosted its position in shares of Denali Therapeutics by 256.5% during the 2nd quarter. Engineers Gate Manager LP now owns 57,430 shares of the company’s stock valued at $1,477,000 after acquiring an additional 41,320 shares during the last quarter. Integrated Wealth Concepts LLC grew its holdings in shares of Denali Therapeutics by 2.7% during the second quarter. Integrated Wealth Concepts LLC now owns 102,241 shares of the company’s stock worth $2,630,000 after purchasing an additional 2,687 shares in the last quarter. Allworth Financial LP increased its position in shares of Denali Therapeutics by 555.0% in the second quarter. Allworth Financial LP now owns 1,834 shares of the company’s stock worth $47,000 after purchasing an additional 1,554 shares during the last quarter. Nykredit A S bought a new position in shares of Denali Therapeutics in the second quarter worth approximately $38,000. Finally, Corient Private Wealth LP purchased a new stake in Denali Therapeutics in the second quarter valued at approximately $301,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Stock Down 2.6%

Shares of NASDAQ DNLI opened at $20.00 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.37 and a quick ratio of 8.32. The stock has a market capitalization of $3.20 billion, a PE ratio of -7.04 and a beta of 1.02. Denali Therapeutics has a one year low of $13.75 and a one year high of $27.30. The business’s fifty day moving average price is $22.84 and its 200-day moving average price is $21.87.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The company had revenue of $3.60 million during the quarter, compared to analyst estimates of $2.15 million. During the same quarter in the prior year, the company earned ($0.72) EPS. On average, equities research analysts anticipate that Denali Therapeutics will post -2.67 EPS for the current year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing medicines for patients with neurodegenerative diseases. The company’s research programs address conditions involving the central nervous system, including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis and lysosomal storage disorders.

Denali’s drug-discovery approach is built around its Transport Vehicle platform, which is designed to help therapeutic molecules cross the blood-brain barrier and reach the brain.